株式会社グローバルインフォメーション
TEL: 044-952-0102
表紙
市場調査レポート

血液癌治療薬の世界市場:2019年〜2023年

Global Blood Cancer Therapeutics Market 2019-2023

発行 TechNavio (Infiniti Research Ltd.) 商品コード 810912
出版日 ページ情報 英文 119 Pages
即納可能
価格
本日の銀行送金レート: 1USD=113.01円で換算しております。
Back to Top
血液癌治療薬の世界市場:2019年〜2023年 Global Blood Cancer Therapeutics Market 2019-2023
出版日: 2019年02月26日 ページ情報: 英文 119 Pages
概要

白血病は小児癌の最も一般的な種類であり、小児患者の癌の中でも最も高い死亡率の原因となっています。白血病の罹患率は著しく高い割合で増加しています。リンパ腫のような他の種類の血液癌の発生も、それがベンダーが新しい分野の研究を行うことにつながっているので、市場成長を牽引するもう一つの要因となっています。ほとんどの薬がリンパ腫および白血病治療のために開発されているので、多くのベンダーが新規治療法の研究に市場に参入するようになります。小児患者における様々なタイプの白血病の高い発生率は、予測期間中に世界の血液癌治療薬市場の主要な推進力の1となると予想されています。 Technavioのアナリストは、世界の血液癌治療薬市場は2023年までに8%以上のCAGRで成長すると予測しています。

当レポートでは、世界の血液癌治療薬市場について調査分析し、市場規模と成長率、市場動向、市場促進要因・課題、市場機会について検証するほか、主要ベンダーなどについて、体系的な情報を提供しています。

目次

第1章 エグゼクティブサマリー

第2章 レポートの範囲

  • イントロダクション1
  • イントロダクション2
  • 米ドルの通貨換算レート

第3章 市場状況

  • 市場エコシステム
  • 市場の特徴
  • 市場セグメンテーション分析

第4章 市場規模

  • 市場の定義
  • 市場規模(2018年)
  • 市場規模および予測(2018年〜2023年)

第5章 ファイブフォース分析

  • バイヤーの交渉力
  • サプライヤーの交渉力
  • 新規参入の脅威
  • 代替品の脅威
  • 競争相手の脅威
  • 市況

第6章 パイプライン

第7章 市場セグメンテーション:タイプ別

  • 市場セグメンテーション:タイプ別
  • 比較:タイプ別市場規模および予測(2018年〜2023年)
  • 白血病
  • リンパ腫
  • 骨髄腫
  • 市場機会:タイプ別

第8章 顧客情勢

第9章 地域情勢

  • 地域別セグメンテーション
  • 地域別比較:市場規模および予測(2018年〜2023年)
  • 北米
  • 欧州
  • アジア
  • その他の地域
  • 主要国
  • 市場機会

第10章 意思決定の枠組み

第11章 成長要因と課題

  • 市場成長要因
  • 市場の課題

第12章 市場動向

第13章 ベンダー情勢

  • 概要
  • 創造的破壊の状況
  • 競合シナリオ

第14章 ベンダー分析

  • 対象ベンダー
  • ベンダー分類
  • ベンダーの市場ポジショニング
  • Bristol-Myers Squibb Company
  • F. Hoffmann-La Roche Ltd
  • Johnson & Johnson Services, Inc.
  • Novartis AG
  • 武田薬品工業

第15章 付録

  • 調査方法
  • 略語のリスト

第16章 TECHNAVIOについて

図表
  • Exhibit 01: Global oncology therapeutics market
  • Exhibit 02: Segments of global oncology therapeutics market
  • Exhibit 03: Market characteristics
  • Exhibit 04: Market segments
  • Exhibit 05: Market definition - Inclusions and exclusions checklist
  • Exhibit 06: Market size 2018
  • Exhibit 07: Global market: Size and forecast 2018-2023 ($ millions)
  • Exhibit 08: Global market: Year-over-year growth 2019-2023 (%)
  • Exhibit 09: Five forces analysis 2018
  • Exhibit 10: Five forces analysis 2023
  • Exhibit 11: Bargaining power of buyers
  • Exhibit 12: Bargaining power of suppliers
  • Exhibit 13: Threat of new entrants
  • Exhibit 14: Threat of substitutes
  • Exhibit 15: Threat of rivalry
  • Exhibit 16: Market condition - Five forces 2018
  • Exhibit 17: Global blood cancer therapeutics market pipeline: Overview
  • Exhibit 18: Global blood cancer therapeutics market pipeline: Overview
  • Exhibit 19: Type - Market share 2018-2023 (%)
  • Exhibit 20: Comparison by type
  • Exhibit 21: Leukemia - Market size and forecast 2018-2023 ($ millions)
  • Exhibit 22: Leukemia - Year-over-year growth 2019-2023 (%)
  • Exhibit 23: Lymphoma - Market size and forecast 2018-2023 ($ millions)
  • Exhibit 24: Lymphoma - Year-over-year growth 2019-2023 (%)
  • Exhibit 25: Myeloma - Market size and forecast 2018-2023 ($ millions)
  • Exhibit 26: Myeloma - Year-over-year growth 2019-2023 (%)
  • Exhibit 27: Market opportunity by type
  • Exhibit 28: Customer landscape
  • Exhibit 29: Market share by geography 2018-2023 (%)
  • Exhibit 30: Geographic comparison
  • Exhibit 31: North America - Market size and forecast 2018-2023 ($ millions)
  • Exhibit 32: North America - Year-over-year growth 2019-2023 (%)
  • Exhibit 33: Top 3 countries in North America
  • Exhibit 34: Europe - Market size and forecast 2018-2023 ($ millions)
  • Exhibit 35: Europe - Year-over-year growth 2019-2023 (%)
  • Exhibit 36: Top 3 countries in Europe
  • Exhibit 37: Asia - Market size and forecast 2018-2023 ($ millions)
  • Exhibit 38: Asia - Year-over-year growth 2019-2023 (%)
  • Exhibit 39: Top 3 countries in Asia
  • Exhibit 40: ROW - Market size and forecast 2018-2023 ($ millions)
  • Exhibit 41: ROW - Year-over-year growth 2019-2023 (%)
  • Exhibit 42: Top 3 countries in ROW
  • Exhibit 43: Key leading countries
  • Exhibit 44: Market opportunity
  • Exhibit 45: Impact of drivers and challenges
  • Exhibit 46: Vendor landscape
  • Exhibit 47: Landscape disruption
  • Exhibit 48: Vendors covered
  • Exhibit 49: Vendor classification
  • Exhibit 50: Market positioning of vendors
  • Exhibit 51: Bristol-Myers Squibb Company - Vendor overview
  • Exhibit 52: Bristol-Myers Squibb Company - Business segments
  • Exhibit 53: Bristol-Myers Squibb Company - Organizational developments
  • Exhibit 54: Bristol-Myers Squibb Company - Geographic focus
  • Exhibit 55: Bristol-Myers Squibb Company - Key offerings
  • Exhibit 56: Bristol-Myers Squibb Company - Key customers
  • Exhibit 57: F. Hoffmann-La Roche Ltd - Vendor overview
  • Exhibit 58: F. Hoffmann-La Roche Ltd - Business segments
  • Exhibit 59: F. Hoffmann-La Roche Ltd - Organizational developments
  • Exhibit 60: F. Hoffmann-La Roche Ltd - Geographic focus
  • Exhibit 61: F. Hoffmann-La Roche Ltd - Segment focus
  • Exhibit 62: F. Hoffmann-La Roche Ltd - Key offerings
  • Exhibit 63: F. Hoffmann-La Roche Ltd - Key customers
  • Exhibit 64: Johnson & Johnson Services, Inc. - Vendor overview
  • Exhibit 65: Johnson & Johnson Services, Inc. - Business segments
  • Exhibit 66: Johnson & Johnson Services, Inc. - Organizational developments
  • Exhibit 67: Johnson & Johnson Services, Inc. - Geographic focus
  • Exhibit 68: Johnson & Johnson Services, Inc. - Segment focus
  • Exhibit 69: Johnson & Johnson Services, Inc. - Key offerings
  • Exhibit 70: Johnson & Johnson Services, Inc. - Key customers
  • Exhibit 71: Novartis AG - Vendor overview
  • Exhibit 72: Novartis AG - Business segments
  • Exhibit 73: Novartis AG - Organizational developments
  • Exhibit 74: Novartis AG - Geographic focus
  • Exhibit 75: Novartis AG - Segment focus
  • Exhibit 76: Novartis AG - Key offerings
  • Exhibit 77: Novartis AG - Key customers
  • Exhibit 78: Takeda Pharmaceutical Company Limited - Vendor overview
  • Exhibit 79: Takeda Pharmaceutical Company Limited - Business segments
  • Exhibit 80: Takeda Pharmaceutical Company Limited - Organizational developments
  • Exhibit 81: Takeda Pharmaceutical Company Limited - Geographic focus
  • Exhibit 82: Takeda Pharmaceutical Company Limited - Key offerings
  • Exhibit 83: Takeda Pharmaceutical Company Limited - Key customers
  • Exhibit 84: Validation techniques employed for market sizing
目次
Product Code: IRTNTR30962

About this market

Leukemia is the most common type of cancer in children and also accounts for the highest mortality rate among cancers in pediatric patients. The prevalence of leukemia has been increasing at a significantly high rate. The incidence of other types of blood cancer such as lymphomas is also another factor driving the growth of the market, as it is leading to vendors conducting research on new areas. Most of the drugs are being developed for both lymphoma and leukemia, thus leading to more vendors entering the market to research on novel therapies. The high incidence of various types of leukemia in pediatric patients is expected to be one of the major drivers of the global blood cancer therapeutics market during the forecast period. Technavio's analysts have predicted that the blood cancer therapeutics market will register CAGR of over 8% by 2023.

Market Overview

Growing adoption of therapeutics

The increasing awareness about the disease, along with the increasing global incidence, is leading to more patients undergoing diagnosis and opting for treatment during the early stages of the disease. This is leading to the increasing adoption of therapeutics for the treatment. These factors are expected to result in the growth of the global blood cancer therapeutics market during the forecast period.

Adverse effects of stem cell transplantation

Bone marrow and stem cell transplantations are some of the most effective treatment options for the treatment of blood cancer types such as leukemia, multiple myeloma, and non-Hodgkin's lymphoma. Although the treatment using stem cells is highly effective for the treatment of cancer, the side effects associated with the treatment are often high. The threat of side effects of stem cell transplant is expected to continue posing a challenge to the market growth during the forecast period.

For the detailed list of factors that will drive and challenge the growth of the blood cancer therapeutics market during the 2019-2023, view our report.

Competitive Landscape

The market appears to be fairly fragmented and with the presence of several vendors. This market research report will help clients identify new growth opportunities and design unique growth strategies by providing a comprehensive analysis of the market's competitive landscape and offering information on the products offered by companies.

TABLE OF CONTENTS

PART 01: EXECUTIVE SUMMARY

PART 02: SCOPE OF THE REPORT

  • 2.1 Preface
  • 2.2 Preface
  • 2.3 Currency conversion rates for US$

PART 03: MARKET LANDSCAPE

  • Market ecosystem
  • Market characteristics
  • Market segmentation analysis

PART 04: MARKET SIZING

  • Market definition
  • Market sizing 2018
  • Market size and forecast 2018-2023

PART 05: FIVE FORCES ANALYSIS

  • Bargaining power of buyers
  • Bargaining power of suppliers
  • Threat of new entrants
  • Threat of substitutes
  • Threat of rivalry
  • Market condition

PART 06: PIPELINE

PART 07: MARKET SEGMENTATION BY TYPE

  • Market segmentation by type
  • Comparison by type
  • Leukemia - Market size and forecast 2018-2023
  • Lymphoma - Market size and forecast 2018-2023
  • Myeloma - Market size and forecast 2018-2023
  • Market opportunity by type

PART 08: CUSTOMER LANDSCAPE

PART 09: GEOGRAPHIC LANDSCAPE

  • Geographic segmentation
  • Geographic comparison
  • North America - Market size and forecast 2018-2023
  • Europe - Market size and forecast 2018-2023
  • Asia - Market size and forecast 2018-2023
  • ROW - Market size and forecast 2018-2023
  • Key leading countries
  • Market opportunity

PART 10: DECISION FRAMEWORK

PART 11: DRIVERS AND CHALLENGES

  • Market drivers
  • Market challenges

PART 12: MARKET TRENDS

PART 13: VENDOR LANDSCAPE

  • Overview
  • Landscape disruption
  • Competitive scenario

PART 14: VENDOR ANALYSIS

  • Vendors covered
  • Vendor classification
  • Market positioning of vendors
  • Bristol-Myers Squibb Company
  • F. Hoffmann-La Roche Ltd
  • Johnson & Johnson Services, Inc.
  • Novartis AG
  • Takeda Pharmaceutical Company Limited

PART 15: APPENDIX

  • Research methodology
  • List of abbreviations

PART 16: EXPLORE TECHNAVIO

Back to Top